Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genetic Services Laboratory, |
RCV001819229 | SCV002067150 | uncertain significance | not specified | 2018-06-11 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002503314 | SCV002790719 | uncertain significance | Congenital neutropenia-myelofibrosis-nephromegaly syndrome | 2022-01-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002503314 | SCV003504594 | uncertain significance | Congenital neutropenia-myelofibrosis-nephromegaly syndrome | 2022-03-10 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 67 of the VPS45 protein (p.Lys67Arg). This variant is present in population databases (no rsID available, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with VPS45-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002542018 | SCV003675026 | uncertain significance | Inborn genetic diseases | 2022-12-19 | criteria provided, single submitter | clinical testing | The c.200A>G (p.K67R) alteration is located in exon 2 (coding exon 2) of the VPS45 gene. This alteration results from a A to G substitution at nucleotide position 200, causing the lysine (K) at amino acid position 67 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |